Inclusion Criteria:  Have atopic dermatitis (AD) for at least 1 year (365 days) prior to the first administration of study intervention as determined by the investigator through participant interview and/or review of the medical history Have a history of inadequate response to treatment for AD with topical medications or for whom topical treatments are otherwise medically inadvisable (example, due to important side effects or safety risks) Have an Eczema Area and Severity Index (EASI) score greater than or equal to (>=) 16 at screening and at baseline Must sign an informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study Must be willing to undergo 4 skin biopsies Have an Investigator Global Assessment (IGA) score >=3 at screening and at baseline Have an involved body surface area (BSA) >=10 percent (%) at screening and at baseline  Exclusion Criteria:  Has a current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances Has ever received any Human interleukin-1 (IL-1) antagonist (example, including but not limited to anakinra, rilonacept)